Pseudomyxoma Peritonei Overview

Save information for later
Sign Up

Learn About Pseudomyxoma Peritonei

What is the definition of Pseudomyxoma Peritonei?
Pseudomyxoma peritonei (PMP) is a rare disease characterized by the presence of mucin in the abdominal (peritoneal) cavity. While the most common cause of PMP is appendix cancer, several types of tumors (including non-cancerous tumors) can cause PMP. Signs and symptoms may include an increase in abdominal size or bloating; inguinal hernia (in men); an ovarian mass that may be felt during a routine pelvic exam (in women); pain or discomfort in the abdomen; and/or appendicitis.
What are the alternative names for Pseudomyxoma Peritonei?
  • Pseudomyxoma peritonei
  • Adenomucinosis
  • Gelatinous ascites
  • PMP
  • Syndrome of pseudomyxoma peritonei
Who are the top Pseudomyxoma Peritonei Local Doctors?
Elite in Pseudomyxoma Peritonei
Dr. David L. Bartlett
Surgical Oncology | General Surgery
Elite in Pseudomyxoma Peritonei
Dr. David L. Bartlett
Surgical Oncology | General Surgery

Allegheny Clinic

2626 Haymaker Rd, Suite 1a, 
Monroeville, PA 
412-681-2300
Languages Spoken:
English
See accepted insurances

David Bartlett is a Surgical Oncologist and a General Surgeon in Monroeville, Pennsylvania. Dr. Bartlett and is rated as an Elite provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Desmoplastic Small Round Cell Tumor, Pancreaticoduodenectomy, and Hepatectomy.

Travis E. Grotz
Elite in Pseudomyxoma Peritonei
Dr. Travis E. Grotz
General Surgery | Surgical Oncology
Elite in Pseudomyxoma Peritonei
Dr. Travis E. Grotz
General Surgery | Surgical Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Travis Grotz is a General Surgeon and a Surgical Oncologist in Rochester, Minnesota. Dr. Grotz and is rated as an Elite provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Pseudomyxoma Peritonei, Stomach Cancer, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Gastrectomy. Dr. Grotz is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Andrew M. Lowy
Distinguished in Pseudomyxoma Peritonei
Dr. Andrew M. Lowy
Surgical Oncology
Distinguished in Pseudomyxoma Peritonei
Dr. Andrew M. Lowy
Surgical Oncology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
858-249-6753
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Lowy is a Surgical Oncologist in San Diego, California. Dr. Lowy and is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Pancreatic Cancer, Pseudomyxoma Peritonei, Pancreatic Ductal Adenocarcinoma, Pancreatectomy, and Small Bowel Resection.

View All Doctors
What are the latest Pseudomyxoma Peritonei Clinical Trials?
A Phase 3, Single-center, Randomized, Controlled Clinical Study to Investigate the Efficacy of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
A Phase 3, Single-center, Randomized, Controlled Clinical Study to Investigate the Efficacy of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Enrollment Status: Recruiting
Publish Date: May 28, 2025
Intervention Type: Biological
Study Phase: Phase 3

Summary: This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\>=) 2 liter ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Fluorouracil-labeled Nascent RNA Technology for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei
Fluorouracil-labeled Nascent RNA Technology for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei
Enrollment Status: Recruiting
Publish Date: February 24, 2025
Intervention Type: Procedure
Study Phase: Not Applicable

Summary: The main objective of this study is to combine HIPEC regimens with Flura-seq to detect the effects of different HIPEC regimens (cisplatin vs. cisplatin+ docetaxel) on the nascent transcriptome of PMP tumors, so as to quantitatively assess the efficacy of different HIPEC regimens in the early stage, and to lay the foundation for optimizing the HIPEC regimens and exploring new therapeutic targets.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center